Hexima Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Geoffrey Kempler

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Geoffrey Kempler (68 yo)

less than a year

Permanencia

Mr. Geoffrey Paul Kempler, B.Sc. Grad. Dipp. App. Soc.Psych, serves as Chairman and Managing Director of Hexima Ltd since September 05, 2023. Mr. Kempler is Chairman of AusBiotech. He Co-Founded Alterity...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Helen Molloy	Financial Controller	no data	AU$224.24k	0.047% A$ 863.4
Marilyn Anderson	Chief Science Officer	14.8yrs	AU$48.63k	1.44% A$ 26.5k
Nancy Sacco	Chief Development Officer	2.4yrs	AU$175.25k	sin datos
Geoffrey Kempler	MD & Chairman	less than a year	sin datos	sin datos
Neil Forrester	Vice President of Business Development	no data	sin datos	sin datos
Leanne Ralph	Company Secretary	2.6yrs	sin datos	sin datos

2.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de HXL se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Geoffrey Kempler	MD & Chairman	less than a year	sin datos	sin datos
Richard Scher	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Tracey Vlahovic	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Phoebe Rich	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Warren Joseph	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Justin Yap	Non-Executive Director	5.8yrs	AU$7.89k	sin datos
Mark Lebwohl	Member of Scientific Advisory Board	no data	sin datos	sin datos
Boni Elewski	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Peter Foley	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Shinichi Watanabe	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Robert Rosen	Member of the Scientific Advisory Board	3.2yrs	sin datos	sin datos
Shari Lipner	Member of the Scientific Advisory Board	2.4yrs	sin datos	sin datos

3.2yrs

Permanencia media

Junta con experiencia: La junta directiva de HXL se considera experimentada (3.1 años de antigüedad promedio).

Hexima Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

No independent directors

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Hexima Limited, Annual General Meeting, Nov 28, 2023

Hexima Limited Appoints Phillip Hains as A Non-Executive Director

Insider recently bought AU$155k worth of stock

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

Recent updates

No independent directors

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Hexima Limited, Annual General Meeting, Nov 28, 2023

Hexima Limited Appoints Phillip Hains as A Non-Executive Director

Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)

New minor risk - Financial data availability

Insider recently bought AU$155k worth of stock

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)

Nicole Van Der Weerden to Step Down as CEO of Hexima Limited

Hexima Limited, Annual General Meeting, Jan 31, 2023

Hexima Limited Announces Board Changes

Less than half of directors are independent

Hexima Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)

Hexima Limited Announces Management Changes

Hexima Limited Announces Phase II Results of Pezadeftide

Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide

Less than half of directors are independent

Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)

Hexima Limited Extends Its Patent Protection for Pezadeftide

Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual Conference

Read This Before Selling Hexima Limited (ASX:HXL) Shares

Hexima Limited Updates Timeline to Phase 2B Results

Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media